Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination

Abstract

Disclosed are methods whereby an effective amount of a HDAC6 inhibitor is used to activate a subjects T-cell response to tumor or tumor vaccine. Methods of using HDAC6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed.

1 . A method of increasing T-cell activation and response against tumor, comprising: administering to a subject having an oncological disorder an amount of a HDAC6 inhibitor effective to increase T-cell activation and response against tumor in the subject, wherein the HDAC6 inhibitor is selected from the group consisting of ACY1215, Tubstatin A, Tubacin, and any combination thereof. 
     
     
         2 . The method of  claim 1 , wherein the inhibitor is ACY1215. 
     
     
         3 . The method of  claim 1 , wherein the inhibitor is Tubstatin A, Tubacin, or any combination thereof. 
     
     
         4 . The method of  claim 1 , wherein the subject is also administered ipilimumab, revlimid, velcade, vemurafenib, or any combination thereof. 
     
     
         5 - 17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the oncological disorder is melanoma, ovarian cancer, breast cancer, or colorectal cancer. 
     
     
         19 . The method of  claim 1 , further comprising administering an effective amount of ionizing radiation to the subject. 
     
     
         20 . The method of  claim 1 , further comprising administering an anticancer agent to the subject.